中国组织工程研究 ›› 2021, Vol. 25 ›› Issue (14): 2155-2160.doi: 10.3969/j.issn.2095-4344.3134

• 骨组织构建 bone tissue construction • 上一篇    下一篇

通络生骨胶囊含药血清对破骨细胞及Toll样受体4/核因子κB信号通路的影响

范思奇1,曾  平1,农  焦2,刘金富2,钱晓芬2   

  1. 1广西中医药大学第一附属医院,广西壮族自治区南宁市    530023;2广西中医药大学研究生学院,广西壮族自治区南宁市   530299
  • 收稿日期:2020-03-02 修回日期:2020-03-06 接受日期:2020-05-19 出版日期:2021-05-18 发布日期:2020-12-30
  • 通讯作者: 曾平,博士,教授,主任医师,广西中医药大学第一附属医院,广西壮族自治区南宁市 530023
  • 作者简介:范思奇,男,1993年生,江西省丰城市人,汉族,2019年广西中医药大学毕业,硕士,医师,主要从事中医药防治股骨头坏死研究。
  • 基金资助:
    国家自然科学基金项目(81960876),项目负责人:曾平;广西地区自然科学基金项目(2017GXNSFAA198296),项目负责人:曾平

Effect of Tongluo Shenggu Capsule-containing serum on osteoclasts and Toll-like receptor 4/nuclear factor-kappa B signaling pathway

Fan Siqi1, Zeng Ping1, Nong Jiao2, Liu Jinfu2, Qian Xiaofen2    

  1. 1The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, Guangxi Zhuang Autonomous Region, China; 2Graduate School of Guangxi University of Chinese Medicine, Nanning 530299, Guangxi Zhuang Autonomous Region, China
  • Received:2020-03-02 Revised:2020-03-06 Accepted:2020-05-19 Online:2021-05-18 Published:2020-12-30
  • Contact: Zeng Ping, MD, Professor, Chief physician, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, Guangxi Zhuang Autonomous Region, China
  • About author:Fan Siqi, Master, Physician, The First Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning 530023, Guangxi Zhuang Autonomous Region, China
  • Supported by:
    the National Natural Science Foundation of China, No. 81960876 (to ZP); the Natural Science Foundation of Guangxi Zhuang Autonomous Region, No. 2017GXNSFAA198296 (to ZP)

摘要:

文题释义:
TLR4/NF-κB 信号通路:MyD88是TLR4信号通路中重要的衔接蛋白,MyD88激活一个死亡域激酶,引起 IRAK自磷酸化,磷酸化的IRAK与肿瘤坏死因子受体相关因子6(TRAF6) 相互作用形成复合物,促使NIK活化,进而活化IKK,降解ⅠκB,释放核因子κB(如 核因子κB p65),由胞质转位到核内,刺激各种细胞因子等的表达。
核因子κB(NF-κB):是一种与炎症因子产生、细胞增殖、细胞外基质交联和细胞凋亡密切相关的转录因子,参与多种炎症的信号转导,在细胞中最常见的作用形式为核因子κB p65及核因子κB p50。

背景:在激素性股骨头坏死发病机制中Toll样受体4(Toll-link receptors 4,TLR4)信号通路异常发挥着重大的作用,调控TLR4有望成为有效治疗激素性股骨头坏死的突破点。
目的:研究通络生骨胶囊对破骨细胞分化过程中TLR4信号传导通路的影响,了解通络生骨胶囊对破骨细胞分化抑制过程的分子生物学机制。
方法:将28只12周龄的C57BL/6小鼠随机分为通络生骨胶囊高、中、低剂量灌胃组[设置0.91 g/(kg•d)为中剂量,该浓度剂量的2倍为高剂量,0.5倍为低剂量]和生理盐水灌胃组,每日1次,持续灌胃14 d。末次给药8 h后,通过腹主动脉取血来制备含药血清和对照血清组。采用核因子κB受体激活蛋白配体和巨噬细胞集落刺激因子诱导因子联合诱导RAW264.7 细胞株,将细胞分为5组:正常组、生理盐水组、通络生骨胶囊含药血清低、中、高浓度组。经CCK-8法观察含药血清对细胞增殖的影响后,选择剂量浓度为20%的含药血清在诱导的第4天干预破骨细胞前体,每组分别在诱导24,48,72,96 h观察破骨细胞前体的生长形态及融合程度,第8天通过TRAP染色来观察破骨细胞的数目,通过Western blot检测关键蛋白TLR4、核因子κBp65的表达,ELISA检测细胞上清液肿瘤坏死因子α的水平。实验方案经广西中医药大学动物实验伦理委员会批准。
结果与结论:①通络生骨胶囊低、中、高剂量组培养液中肿瘤坏死因子α水平均低于正常组(P < 0. 01),通络生骨胶囊低剂量组与中剂量组之间差异无显著性意义;②通络生骨胶囊高、中、低剂量组TLR4蛋白表达均显著低于正常组(P < 0.05);通络生骨胶囊组中剂量、高剂量组核因子κBp65蛋白表达显著低于正常组(P < 0.05);其中TLR4、核因子κBp65蛋白的表达在通络生骨胶囊中剂量组中抑制效果最为有效;③结果说明,通络生骨胶囊治疗激素性股骨头坏死的机制之一可能是通过抑制TLR4//NF-κB信号通路,减少了下游的炎症因子肿瘤坏死因子α的释放,改善了激素性股骨头坏死中的炎症环境;另一方面又抑制了破骨细胞活性,使骨吸收减弱,改善了激素性股骨头坏死中的骨代谢平衡。

https://orcid.org/0000-0003-0229-6055 (范思奇) 

中国组织工程研究杂志出版内容重点:组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松;组织工程

关键词: 复方中药, 因子, 骨吸收, 破骨细胞, Toll 样受体 4, 核因子κB, RAW264.7细胞

Abstract: BACKGROUND: Abnormal Toll-like receptor 4 (TLR4) signaling pathway plays an important role in the pathogenesis of steroid-induced necrosis of femoral head, and regulating TLR4 expression is expected to become a breakthrough point for effective treatment of hormonal femoral head necrosis.
OBJECTIVE: To study the effect of Tongluo Shenggu Capsule on the TLR4 signal transduction pathway in the process of osteoclast differentiation, in order to understand the molecular biological mechanism by which Tongluo Shenggu Capsule inhibits osteoclast differentiation.
METHODS: Twenty-eight 12-week-old C57BL/6 mice were randomly divided into Tongluo Shenggu Capsule high-dose, medium-dose, low-dose gavage group and normal saline gavage group. Medium dose was set to be 0.91 g/(kg·d), the high dose was 2 times up on the medium dose, and the low dose was 0.5 time up on the medium dose. The drug-containing serum was prepared by continuous gavage for 14 days. At 8 hours after the last administration, blood samples were taken from the abdominal aorta to prepare the serum containing the drug and the control serum. RAW264.7 cell line was induced by the combination of receptor activator of nuclear factor kappa B ligand and macrophage colony stimulating factor inducer. The cells were divided into five groups: normal group, normal saline group, high-, medium-, and low-dose drug-containing serum groups. Cell counting kit-8 method was used to observe the effect of drug-containing serum on cell proliferation. Then, the precursor of osteoclast was pretreated with 20% drug-containing serum on the 4th day of induction. Cell growth, morphology, and fusion were observed at 24, 48, 72, and 96 hours after induction. The number of osteoclasts was observed by TRAP staining on the 8th day. The expression of TLR4 and NF-κBp65 in cell supernatant was detected by western blot. The level of tumor necrosis factor α in cell supernatant was detected using ELISA. The study protocol was approved by the Animal Experimental Ethics Committee of Guangxi University of Chinese Medicine.
RESULTS AND CONCLUSION: The level of tumor necrosis factor α in low-, medium- and high-dose drug-containing serum groups was lower than that in the normal group (P < 0.01), whereas there was no significant difference between the low-dose and medium-dose drug-containing serum groups. The protein expression of TLR4 in low-, medium- and high-dose drug-containing serum groups was significantly lower than that in the normal group (P < 0.05), whereas the protein expression of NF-κBp65 in the medium- and high-dose drug-containing serum groups was significantly lower than that in the normal group (P < 0.05). Moreover, inhibiting the protein expression of TLR4 and NF-κBp65 was most obvious in the medium-dose drug-containing serum group. Overall, one of the mechanisms underlying Tongluo Shenggu Capsule in the treatment of steroid-induced necrosis of femoral head may be to reduce the release of tumor necrosis factor α and improve the inflammatory environment by inhibiting TLR4/NF-κB signal pathway; on the other hand, it can inhibit the activity of osteoclasts, weaken bone absorption and improve the balance of bone metabolism after steroid-induced necrosis of femoral head.


Key words: compound traditional Chinese medicine, factor, bone resorption, osteoclast, Toll-like receptor 4, nuclear transcription factor-B, RAW264.7 cell

中图分类号: